14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VOR vs ATAI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
VOR Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 4–4 Matrix Metrics)
VOR Overall Winner
6-Pillar Tally: VOR 4 – 1 ATAI (1 Tie)
Matrix Metrics: VOR 4 – 4 ATAI
As of Nov 16, 2026, Vor Biopharma Inc. (VOR) is the stronger overall head-to-head candidate over ATAI Life Sciences N.V. Common Shares (ATAI) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VOR carries a Unified Composite Score of 57.8/100 (HOLD) at $19.26 (N/M Forward P/E, 0.0% operating margin), whereas ATAI carries 45.7/100 (HOLD) at $7.35 (N/M Forward P/E, -2590.4% operating margin).
Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. ATAI 45.7/100 HOLD) and 1.91β · 61% Vol risk profile, whereas ATAI leads top-line expansion (+137.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VOR vs ATAI. Trailing 12-month operating profitability (VOR 0.0% vs ATAI -2590.4%) and valuation multiples (VOR N/M vs ATAI N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.7B market capitalization and -2590.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VOR vs ATAI Key Questions & Quantitative Answers
As of Nov 16, 2026, Vor Biopharma Inc. (VOR) is the stronger overall head-to-head candidate over ATAI Life Sciences N.V. Common Shares (ATAI) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VOR carries a Unified Composite Score of 57.8/100 (HOLD) at $19.26 (N/M Forward P/E, 0.0% operating margin), whereas ATAI carries 45.7/100 (HOLD) at $7.35 (N/M Forward P/E, -2590.4% operating margin). Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. ATAI 45.7/100 HOLD) and 1.91β · 61% Vol risk profile, whereas ATAI leads top-line expansion (+137.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
ATAI leads the Growth & Scale pillar: VOR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ATAI at +137.0% YoY revenue growth and -96.8% YoY earnings growth on $4.5M TTM revenue (N/A gross margin, -2590.4% operating margin). On trailing 12-month operating scale, VOR generates N/A in USD-normalized revenue versus $4.5M for ATAI. In operating R&D and SG&A reinvestment, VOR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATAI.
VOR screens cheaper on headline valuation multiples. VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ATAI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VOR (-125.4% ROE) versus ATAI (-417.2% ROE) capital efficiency.
In options market volatility and institutional positioning, VOR carries 127.0% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.91β · 61% Vol realized risk). By comparison, ATAI carries 44.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.76x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.13β · 10% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.